Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL

Darko Antic1,2*, Natasa Milic3, Thomas Chatzikonstantinou4,5, Lydia Scarfò6, Vladimir Otasevic1, Nina Rajovic3, David Allsup7, Alejandro Alonso Cabrero8, Martin Andres9, Monica Baile Gonzales10, Antonella Capasso11, Rosa Collado12,13, Raul Cordoba14, Carolina Cuéllar-García15, Juan Gonzalez Correa16, Lorenzo De Paoli17, Maria Rosaria De Paolis18, Giovanni Del Poeta19, Maria Dimou20, Michael Doubek21,22, Maria Efstrapopoulos23, Shaimaa El-Ashwah24, Alicia Enrico25, Blanca Espinet26, Lucia Farina27, Angela Ferrari28, Myriam Foglietta29, Alberto Lopez-Garcia14, José A. García-Maro30, Rocío García-Serra12,13, Massimo Gentile31, Eva Gimeno26, Maria Gomes da Silva32, Odit Gutwein33,34, Yervand K. Hakobyan35, Yair Herishanu36, José Ángel Hernández-Rivas37, Tobias Herold38, Gilad Itchaki39, Ozren Jaksic40, Ann Janssens41, Olga B. Kalashnikova42, Elżbieta Kalicińska43, Arnon P. Kater44, Sabina Kersting45, Maya Koren-Michowitz33,34, Jorge Labrador46, Deepesh Laq47, Luca Laurenti48,49, Alberto Fresa48,49, Mark-David Levin50, Carlota Mayor Bastida48,851, Lara Malerba52, Roberto Marascà53, Monia Marchetti54, Juan Marquet55, Biljana Mihaljevic1,2, Ivana Milosevic36, Fatima Mirás57, Marta Morawska58,59, Marina Motta60, Talha Munir61, Roberta Murru62, Raquel Nunes32, Jacopo Oliveri63, Miguel Arturo Pavlovsky64, Inga Piskunova65, Viola Maria Popov66, Francesca Maria Quaglia67, Giulia Quaresmini68, Gianluigi Reda69, Gian Matteo Rigolin70, Amit Shrestha71, Martin Šimkovič72, Svetlana Smirnova65, Martin Špaček73, Paolo Sportoletti74, Qana Stanca75, Niki Stavroyianni4, Doreen Te Raa76, Kristina Tomic1, Sanne Tonino77, Livio Trentin78, Ellen Van Der Spek79, Michel van Gelder80, Marzia Varettoni81, Andrea Visentin78, Candida Vitale82, Vojin Vukovic1, Ewa Wasik-Szczepanek83, Tomasz Wróbel83, Lucrecia Yañez San Segundo84, Mohamed Yassin85, Marta Coscia82, Alessandro Rambaldi68, Emili Montserrat16, Robin Foà86, Antonio Cuneo70, Marc Carrier87, Paolo Ghia61 and Kostas Stamatopoulos5†

*Correspondence: darko.antic1510976@gmail.com

1 Lymphoma Center, Clinic for Hematology, University Clinical Center of Serbia, Belgrade, Serbia

Full list of author information is available at the end of the article
### Abstract

**Background:** Patients with chronic lymphocytic leukemia (CLL) may be more susceptible to COVID-19 related poor outcomes, including thrombosis and death, due to the advanced age, the presence of comorbidities, and the disease and treatment-related immune deficiency. The aim of this study was to assess the risk of thrombosis and bleeding in patients with CLL affected by severe COVID-19.

**Methods:** This is a retrospective multicenter study conducted by ERIC, the European Research Initiative on CLL, including patients from 79 centers across 22 countries. Data collection was conducted between April and May 2021. The COVID-19 diagnosis was confirmed by the real-time polymerase chain reaction (RT-PCR) assay for SARS-CoV-2 on nasal or pharyngeal swabs. Severe cases of COVID-19 were defined by hospitalization and the need of oxygen or admission into ICU. Development and type of thrombotic events, presence and severity of bleeding complications were reported during treatment for COVID-19. Bleeding events were classified using ISTH definition. STROBE recommendations were used in order to enhance reporting.

**Results:** A total of 793 patients from 79 centers were included in the study with 593 being hospitalized (74.8%). Among these, 511 were defined as having severe COVID: 162 were admitted to the ICU while 349 received oxygen supplementation outside the ICU. Most patients (90.5%) were receiving thromboprophylaxis. During COVID-19 treatment, 11.1% developed a thromboembolic event, while 5.0% experienced bleeding. Thrombosis developed in 21.6% of patients who were not receiving thromboprophylaxis, in contrast to 10.6% of patients who were on thromboprophylaxis. Bleeding episodes were more frequent in patients receiving intermediate/therapeutic versus prophylactic doses of low-molecular-weight heparin (LWMH) (8.1% vs. 3.8%, respectively) and in elderly. In multivariate analysis, peak D-dimer level and C-reactive protein to albumin ratio were poor prognostic factors for thrombosis occurrence (OR = 1.022, 95%CI 1.007–1.038 and OR = 1.025, 95%CI 1.001–1.051, respectively), while thromboprophylaxis use was protective (OR = 0.199, 95%CI 0.061–0.645). Age and LMWH intermediate/therapeutic dose administration were prognostic factors in multivariate model for bleeding (OR = 1.062, 95%CI 1.017–1.109 and OR = 2.438, 95%CI 1.023–5.813, respectively).

**Conclusions:** Patients with CLL affected by severe COVID-19 are at a high risk of thrombosis if thromboprophylaxis is not used, but also at increased risk of bleeding under the LMWH intermediate/therapeutic dose administration.

**Keywords:** CLL, COVID-19, Thrombosis, Bleeding, D-dimer, Anticoagulation therapy, Thromboprophylaxis, LMWH, Age

---

### Background

High rates of venous thromboembolism (VTE), predominantly pulmonary embolism (PE), have been documented in patients with coronavirus disease 2019 (COVID-19), particularly in critically ill patients admitted to the intensive care unit (ICU) [1, 2]. Despite the use of prophylactic or even therapeutic doses of anticoagulation therapy, thromboembolic complications have developed in many patients, implying that the risk of thrombotic complications remains high despite treatment, while also prompting the use of higher than usual doses of anticoagulants in hospital settings [3, 4]. The pathophysiology of this prothrombotic state is multifactorial and not yet completely elucidated. However, immune dysregulation [5], endotheliopathy [6] and coagulopathy [7] are distinctive elements of COVID-19 that have a major impact on thrombosis development.

The use of anticoagulation therapy, particularly at intermediate and therapeutic doses, is associated with an increased risk of haemorrhagic events [8]. Initial reports revealed limited evidence of COVID-19 therapy-related bleeding, but more data concerning the risk of bleeding are accumulating, particularly as regards the use of therapeutic doses of anticoagulation therapy [9]. Considering the ongoing pandemic and its impact on vulnerable groups of patients, it is of immense importance to assess the actual rate of both thrombotic and bleeding events in specific patient populations.

Chronic lymphocytic leukemia (CLL) is the most prevalent leukemia in the western world [10]. Patients with CLL may be more susceptible to COVID-19-related poor outcomes, such as thrombosis and death [11]. Due to advanced age, the presence of various comorbidities, and the inherent immune deficiency of patients with CLL, there is a need for a robust analysis of the effects of patient and CLL-related characteristics, and thromboprophylactic therapy to define the optimal management of these patients during the COVID-19 pandemic.
In this retrospective international multicenter study, we assessed the risk of thrombosis as well as the risk of bleeding due to the administration of thromboprophylaxis in severely ill patients with CLL and COVID-19 and sought to identify potential predictors of thrombosis.

**Methods**

### Data collection

This is a retrospective multicenter study conducted by ERIC, the European Research Initiative on CLL, including patients from 79 centers across 22 countries. Data collection was conducted between April and May 2021. The study was approved by the ethics committees of the collaborating institutions. This cohort of CLL patients represents a subgroup of recently published ERIC and Campus CLL study [12].

In adherence to the international standard of practice, the criteria for COVID-19 diagnosis were positive real-time polymerase chain reaction (RT-PCR) assay for SARS-CoV-2 on nasal or pharyngeal swabs. Patients whose radiological or clinical assessments were suspicious of COVID-19, but had a negative swab test, were not included in the study.

The CLL diagnostic procedures, patient assessment, clinical decisions, and actual treatment were performed by local hematology teams following international CLL guidelines [13, 14].

The following patient clinical characteristics and laboratory data were obtained in the survey: baseline demographics; CLL diagnosis date; treatment status; presence, number, and type of comorbidities [cumulative illness rating scale (CIRS)], date of COVID-19 diagnosis; symptoms, treatment, and outcome of COVID-19; need for and duration of hospitalization; type of ward (intensive care unit (ICU) vs. non-ICU ward); peak absolute lymphocyte count (ALC); peak C-reactive protein (CRP); nadir albumin level; peak D-dimer level; use, type, and dosage of thromboprophylaxis; development and type of thrombotic events, presence and severity of bleeding complications during the hospitalization for COVID-19. Dosage of low-molecular weight heparin (LMWH) was defined as: prophylactic dose 50 IU/kg s.c. daily, intermediate dose 100 IU/kg s.c. daily and therapeutic dose 200 IU/kg s.c. daily. The use of extended thromboprophylaxis after discharge from hospitalization was defined as prophylactic dosage of anticoagulation administered to patients at high risk for VTE for up to 39 days post-discharge [15]. Thrombotic events were classified as: pulmonary embolism (PE), deep vein thrombosis (DVT), stroke, myocardial infarction (MI), line associated thrombosis, extracorporeal circuit clotting in haemodialysis or ECMO lines and pernio-like skin lesions. Bleeding events have been classified as major using the International Society on Thrombosis and Haemostasis (ISTH) definition, whereas all non-major bleeding events were classified as minor [16].

To eliminate collection bias, we restricted our analysis to the group of patients who were considered to have severe COVID-19. Severe COVID-19 was defined as hospitalization and need of oxygen or admission into ICU while nonsevere/mild COVID-19 was defined as confinement at home or hospitalization without need of oxygen [12].

In order to enhance reporting, we used the Strengthening the Reporting of Observational studies in Epidemiology (STROBE) checklist, which is an evidence-based, minimum set of recommendations for reporting observational studies in biomedical sciences [17].

### Statistical analysis

Numerical data were presented as means with standard deviation or with median with 25–75th percentile. Categorical variables are summarized as absolute numbers with percentages or rates with corresponding 95% confidence intervals (CIs). The Kolmogorov–Smirnov test was used to assess the normality of data distribution. Student’s t-test for independent samples or the Mann–Whitney U test was applied for numerical variables according to the data distribution. For categorical variables, Pearson’s chi square analysis and Fisher’s exact test were used. Predictors of thrombosis and bleeding occurrence during treatment were identified using univariate and multivariate logistic regression analyses, and presented with odds ratios (ORs) and corresponding 95% CIs. Variables were selected based on their associations with increased risk for thrombosis and bleeding (p < 0.10; univariate analysis) or known relevance, and were included in the variable pool for a stepwise-regression model. No imputation methods were used in analysis. If an outcome was missing, the patient data was excluded from the analysis. Receiver operating characteristic (ROC) curve analysis was used to test the model’s discrimination performance based on sensitivity and specificity. Statistical analysis was performed using IBM SPSS statistical software (SPSS for Windows, release 25.0, SPSS, Chicago, IL, USA).

### Results

We collected data from a total of 793 patients with SARS-CoV-2 infection (Fig. 1). Most patients (742; 93.6%) were diagnosed with CLL, while 36 (4.5%) and 15 (1.9%) were diagnosed with small lymphocytic lymphoma (SLL) and monoclonal B-cell lymphocytosis (MBL), respectively. The patients were predominantly men (69.5%), with a median age of 69 years (25th–75th percentile: 61–77 years). Five hundred and ninety-three (74.8%)
patients were admitted to the hospital. Among these, 349 needed oxygen supplementation outside the ICU, while 162 were admitted to the ICU. Further analysis was restricted to this group of patients (n = 511) who were considered to have severe COVID-19. Median follow-up time i.e., duration of hospitalization for CLL patients with severe COVID-19 was 16 days (25–75th percentile, 10–26 days).

CLL patients with severe COVID-19 were predominantly male (69.5%), with a median age of 70 years (25th–75th percentile, 63–79 years). Most cases had a significant burden of two or more comorbidities (62.9%), with hypertension (49.9%), diabetes (22.2%), coronary artery disease (12.2%), arrhythmias (9.8%), and other cardiovascular comorbidities and non-hematological malignancy (8.8% and 7.5%, respectively) being the most common. The reported median CIRS score was 4 (25th–75th percentile, 2–7). Forty-five percent were treatment naive (“watch and wait”), while 55% had received at least one line of CLL therapy (median, 1; range 1–5). At the time of COVID-19 diagnosis, 34.3% of patients were receiving active CLL therapy, most commonly Bruton tyrosine kinase inhibitors (BTKi’s) (54.9%).

Out of 511 CLL patients with severe COVID-19, data regarding thromboembolic events were available for 460, while data regarding bleeding were available for 468 patients. In this cohort of severe COVID-19 patients with CLL, 11.1% of patients (51/460, 95% CI 8–14%) developed thromboembolic events during treatment for COVID-19: 37 patients developed PE (8.0%), 7 patients deep vein thrombosis (1.5%), 5 patients stroke (1.1%), 2 myocardial infarction (0.4%), one patient developed line associated thrombosis and one developed pernio-like skin lesions. There were no extracorporeal circuit clotting in haemodialysis or ECMO lines. A total of 4.1% (19/460) of deaths were suspected to be related to thrombosis (Table 1). Twenty-three patients (23/468, 4.9%, 95% CI 3–7%) experienced bleeding during COVID-19 treatment (12 major bleeding; 11 non-major bleeding cases). Detailed information about patient characteristics according to thrombosis and bleeding status is presented in Table 2. There were no differences in baseline patient characteristics between patients who developed thrombosis during COVID-19 treatment versus those who did not develop thrombosis, with the exception of the presence of other cardiovascular diseases. Patients who experienced bleeding were significantly older than patients who did not experience bleeding.

Patients with CLL and severe COVID-19 presented with fever (82.6%), and respiratory symptoms, including dyspnea (60.6%) and cough (53.8%). Other symptoms included fatigue (22.1%), headache (5.7%), myalgias/arthritis (9.5%), anosmia/ageusia (4.9%), and gastrointestinal symptoms (10.1%). Other symptoms were observed in 15.6% patients. Data regarding specific

### Table 1: Thrombosis and bleeding in CLL patients during hospitalization for severe COVID-19

| Event                      | n/N         | 95% CI    |
|----------------------------|-------------|-----------|
| **Thrombosis overall**     | 51/460 (0.11) | 0.08–0.14 |
| Pulmonary embolism         | 37/51       |           |
| Deep vein thrombosis       | 7/51        |           |
| Ischaemic stroke           | 5/51        |           |
| Myocardial infarction      | 2/51        |           |
| Line associated thrombosis | 1/51        |           |
| Pernio-like skin lesions   | 1/51        |           |
| **Thrombosis-related death** | 19/460 (0.04) | 0.02–0.06 |
| **Bleeding overall**       | 23/468 (0.05) | 0.03–0.07 |
| Major                      | 12/23       |           |
| Gastrointestinal           | 6/12        |           |
| CNS/haemorrhagic stroke    | 3/12        |           |
| Intramuscular              | 3/12        |           |
| Minor*                     | 11/23       |           |
| Epistaxis                  | 5/11        |           |
| Skin                       | 4/11        |           |
| Genitourinary              | 2/11        |           |
| Gastrointestinal           | 1/11        |           |
| Conjunctival               | 1/11        |           |

*Two patients had more than one event
### Table 2  Characteristics of the present cohort according to thrombosis and bleeding status

|                  | Thrombosis | Bleeding |
|------------------|------------|----------|
|                  | No (n = 409) | Yes (n = 51) | No (n = 445) | Yes (n = 23) |
| Gender, male, %  | 283/409 (69.2) | 35/51 (68.6) | 313/445 (70.3) | 15/23 (65.2) |
| Age, median (25–75th percentile) | 70 (63–79) | 67 (61–77) | 69 (63–78) | 78 (66–86)* |
| Smoking          |             |           |               |              |
| Never, %         | 253/378 (66.9) | 31/48 (64.6) | 275/414 (66.4) | 13/21 (61.9) |
| Ex-smoker, %     | 96/378 (25.4) | 13/48 (27.1) | 108/414 (26.1) | 6/21 (28.6) |
| Current smoker, %| 29/378 (7.7)  | 4/48 (8.3)  | 31/414 (7.5)  | 2/21 (9.5)   |
| Obesity, %       | 71/390 (18.2) | 8/50 (16.0)  | 73/425 (17.2) | 5/21 (23.8)  |
| Presence of any comorbidity, % | 339/408 (83.1) | 45/50 (90.0) | 367/443 (82.8) | 19/23 (82.6) |
| Number of comorbidities |             |           |               |              |
| No comorbidities, % | 69/408 (16.9) | 5/50 (10.0)  | 76/443 (17.2) | 4/23 (17.4)  |
| 1 comorbidity, %  | 86/408 (21.1) | 14/50 (28.0) | 91/443 (20.5) | 6/23 (26.1)  |
| > 2 comorbidities, % | 253/408 (62.0) | 31/50 (62.0) | 276/443 (62.3) | 13/23 (56.5) |
| Type of comorbidities |             |           |               |              |
| Other respiratory, % | 25 (6.1) | 6 (12.0) | 33 (7.4) | 2 (8.7)  |
| Asthma, %        | 12 (2.9) | 1 (2.0) | 14 (3.2) | 0 (0) |
| COPD, %          | 26 (6.4) | 1 (2.0) | 30 (6.8) | 1 (4.3)  |
| Other cardiovascular, % | 31 (7.6) | 8 (16.0)*  | 39 (8.8) | 0 (0)  |
| Cardiac failure, % | 12 (2.9) | 1 (2.0) | 11 (2.5) | 2 (8.7)  |
| Arrhythmias, %   | 35 (8.6) | 8 (16.0) | 40 (9.0) | 4 (17.4) |
| Coronary artery disease, % | 43 (10.5) | 4 (8.0) | 47 (10.6) | 1 (4.3)  |
| Hypertension, %  | 202 (49.5) | 23 (46.0) | 216 (48.8) | 12 (52.2) |
| Diabetes, %      | 95 (23.3) | 11 (22.0) | 101 (22.8) | 4 (17.4)  |
| Other hematological malignancy, % | 6 (1.5) | 2 (4.0) | 6 (1.4) | 1 (4.3)  |
| Other non-hematological malignancy, % | 30 (7.4) | 5 (10.0) | 35 (7.9) | 2 (8.7) |
| Chronic renal disease, % | 26 (6.4) | 4 (8.0) | 27 (6.1) | 2 (8.7)  |
| CIRS, median (25–75th percentile) | 4 (2–7) | 4 (2–7) | 4 (2–7) | 4 (2–7)  |

COPD chronic obstructive pulmonary disease, CIRS cumulative illness rating scale
*p < 0.05

### Table 3  Presenting symptoms of severe COVID-19 according to thrombosis and bleeding status of CLL patients with COVID-19

|                  | Thrombosis | Bleeding |
|------------------|------------|----------|
|                  | No (n = 409) | Yes (n = 51) | No (n = 445) | Yes (n = 23) |
| Fever            | 340/408 (83.3) | 41/51 (80.4) | 368/444 (82.9) | 19/23 (82.6) |
| Dyspnea          | 241/406 (59.4) | 33/51 (64.7) | 264/441 (59.9) | 15/23 (65.2) |
| Cough            | 223/408 (54.7) | 25/51 (49.0) | 239/444 (53.8) | 11/23 (47.8) |
| Fatigue          | 86/408 (21.1) | 9/51 (17.6)  | 94/444 (21.2) | 4/23 (17.4)  |
| Headache         | 24/408 (5.9)  | 4/51 (7.8)   | 23/444 (5.2)  | 3/23 (13.0)  |
| GI symptoms      | 46/408 (11.3) | 3/51 (5.9)   | 45/444 (10.1) | 4/23 (17.4)  |
| Anosmia/Ageusia  | 20/408 (4.9)  | 4/51 (7.8)   | 21/444 (4.7)  | 2/23 (8.7)   |
| Myalgia/Arthralgia | 38/408 (9.3) | 5/51 (9.8)   | 41/444 (9.2)  | 2/23 (8.7)   |

GI gastrointestinal
*p < 0.05
symptoms manifested during COVID-19 are presented according to thrombosis and bleeding status in Table 3. There was no statistically significant difference in symptoms between the groups.

One hundred and seventy five (34.3%) patients were receiving active CLL-directed therapy while ill with COVID-19 though, 140 (80.5%) stopped the CLL treatment after the infection. BTK inhibitors (n = 95) were the most common therapy used (54.9% of patients receiving CLL therapy). Neither continuation nor discontinuation of BTKi in CLL patients with COVID-19 infection impacted thrombosis and bleeding occurrence in patients with CLL (Table 4). Venetoclax was administered as monotherapy in 21 patients, and in combination with anti-CD20 monoclonal antibodies in 12 patients. A minority of patients received other therapies, including anti-CD20 monoclonal antibody monotherapy (n = 5) and phosphatidylinositol-3-kinase (PI3K) inhibitors monotherapy (n = 5), while a combination of anti-CD20 monoclonal antibodies and PI3K inhibitors received one patient. Fifteen patients received either chemotherapy or chemoimmunotherapy. Corticosteroids for CLL were administered to 12.0%.

Pharmacological treatment for COVID-19 included antivirals (45.6%), azithromycin (40.5%), hydroxychloroquine or similar drugs (37.9%), anti-IL6 or anti-IL6R

### Table 4

| CLL-directed therapy and COVID-19 management strategies according to thrombosis and bleeding status of CLL patients with COVID-19 |
|---------------------------------------------------------------|
| **Thrombosis** | **Bleeding** |
| Yes (n = 51) | Yes (n = 23) | Yes (n = 23) |
| No (n = 409) | No (n = 445) |
| On CLL treatment at the time of COVID-19 | 132 (32.4) | 21 (41.2) | 149 (32.7) | 11 (47.8) |
| On treatment with corticosteroids for CLL or other disease | 46 (11.6) | 6 (11.8) | 49 (11.3) | 3 (13.0) |
| Anti-CD20 at the time of COVID-19 | 27 (6.7) | 3 (5.9) | 25 (5.7) | 2 (8.7) |
| Type of CLL treatment at the time of COVID-19 | | | | |
| BTKi only | 69 (16.3) | 10 (20.0) | 83 (54.6) | 4 (18.2) |
| Venetoclax | 14 (3.4) | 2 (4.0) | 16 (10.9) | 4 (18.2) |
| Venetoclax + Anti-CD20 | 11 (2.5) | 2 (4.0) | 9 (6.0) | 2 (9.1) |
| PI3K inhibitors | 5 (1.2) | 0 (0.0) | 5 (3.4) | 0 (0.0) |
| Anti-CD20 only | 4 (1.0) | 1 (2.0) | 4 (2.7) | 0 (0.0) |
| Chemotherapy | 10 (2.4) | 2 (4.0) | 11 (7.5) | 1 (4.3) |
| Chemoimmunotherapy | 12 (2.9) | 2 (4.0) | 13 (8.7) | 0 (0.0) |
| BTKi + Venetoclax | 2 (0.5) | 0 (0.0) | 2 (1.4) | 0 (0.0) |
| Steroids only | 3 (0.7) | 1 (2.0) | 4 (2.7) | 0 (0.0) |
| Managing CLL treatment | | | | |
| Continued as planned | 25 (19.1) | 5 (23.8) | 30 (20.3) | 2 (18.2) |
| Replaced with another treatment | 0 (0.0) | 1 (4.8) | 0 (0.0) | 1 (9.1) |
| Stopped treatment | 106 (81.8) | 15 (71.4) | 118 (79.7) | 8 (72.7) |
| Managing BTKi treatment | | | | |
| BTKi at the time of COVID-19 | 71 (54.6) | 10 (47.6) | 85 (57.8) | 4 (18.2) |
| Continued BTKi as planned | 20 (28.2) | 3 (30.0) | 24 (82.8) | 1 (25.0) |
| Stopped BTKi treatment | 51 (71.8) | 7 (70.0) | 61 (81.8) | 3 (75.0) |
| Pharmacological treatment for COVID-19 | | | | |
| Convalescent hyperimmune plasma | 28 (9.2) | 5 (13.5) | 30 (9.1) | 5 (27.8)* |
| Antivirals | 160 (44.7) | 24 (53.3) | 181 (46.4) | 9 (40.9) |
| Hydroxychloroquine or similar | 139 (39.0) | 14 (32.6) | 150 (38.9) | 8 (36.4) |
| Azithromycin | 143 (40.7) | 17 (39.5) | 158 (41.6) | 7 (31.8) |
| Steroids | 320 (82.1) | 47 (95.9)* | 354 (83.7) | 21 (91.3) |
| Anti-IL6 or anti-IL6R | 57 (16.3) | 19 (42.2)* | 70 (18.4) | 7 (31.8) |
| ICU admission | 109 (28.7) | 2 (9.6) | 128 (28.8) | 9 (39.1) |
| Supportive therapy, ECMO | 2 (0.5) | 2 (3.9)* | 2 (445 (0.4)) | 2 (23 (8.7)* |

**CLL** chronic lymphocytic leukemia, **BTKi** Bruton tyrosine kinase inhibitors, **COVID-19** coronavirus disease 2019, **PI3K** phosphatidylinositol-3-kinase inhibitors, **ICU** intensive care unit, **ECMO** Extracorporeal membrane oxygenation

*p < 0.05
monoclonal antibodies (19.1%), and convalescent hyperimmune plasma (10.1%). Steroids were administered to 83.4% of patients. Extracorporeal membrane oxygenation (ECMO) was used in 5 patients (1%). CLL-directed therapy and COVID-19 management strategies according to thrombosis and bleeding status are presented in Table 4. Steroids use for COVID-19, anti-IL6 or anti-IL6R treatment and admission to ICU were more common among patients who developed thrombosis in contrast to patients who did not develop thrombosis. Use of convalescent hyperimmune plasma was more common among patients who experienced bleeding in contrast to patients who did not experience bleeding. Use of supportive ECMO therapy was more common among patients who developed both thrombosis and bleeding.

The biochemical characteristics of the patients according to thrombosis and bleeding status are shown in Table 5. Peak D-dimer level was significantly higher in patients who developed thrombosis in contrast to patients who did not develop thrombosis, as well as in patients who experienced bleeding in contrast to patients who did not experience bleeding.

Most patients (90.5%) were receiving thromboprophylaxis for COVID-19: 85.9% received LMWH, 3.6% received direct oral anticoagulants (DOACs), and 1.1% aspirin. Five patients treated with ECMO and three patients on haemodialysis were switched to unfractionated heparin (UFH) after initial LMWH approach. Thrombosis developed in 21.6% of patients who were not receiving thromboprophylaxis in contrast to 10.6% of patients who were on thromboprophylaxis ($p=0.043$). Prophylactic dose was administered to 68.1%, intermediate to 14.3% and therapeutic to 17.7% of patients who received LMWH. Patients receiving intermediate/therapeutic doses of LMWH experienced more frequent thrombosis than patients who received prophylactic doses (22/126, 17.5% vs. 18/261, 6.9%, respectively) ($p=0.001$), and experienced more frequent bleeding (10/124, 8.1% vs. 10/262, 3.8%, respectively) ($p=0.079$). Extended thromboprophylaxis was administered to 26.8% of patients.

In univariate logistic regression analysis, admission to ICU, anti-IL6 or anti-IL6R treatment and steroids use for COVID-19 were predictive of thrombosis occurrence, ($p<0.001$, OR = 3.086, 95%CI 1.707–5.578; $p<0.001$, OR = 3.744, 95%CI 1.942–7.215 and $p=0.026$, OR = 5.141, 95%CI 1.220–21.665, respectively). High C-reactive protein to albumin ratio and D-dimer values were also predictive of thrombosis occurrence ($p=0.049$, OR = 0.428, 95%CI 0.184–0.996). Presence of other cardiovascular diseases was of borderline significance ($p=0.050$, OR = 2.316, 95%CI 1.000–5.366). In multivariate analysis, peak D-dimer level, high C-reactive protein to albumin ratio and anti-IL6 or anti-IL6R treatment were poor prognostic factors for thrombosis occurrence ($p=0.005$, OR = 1.022, 95%CI 1.007–1.053 and $p=0.002$, OR = 1.016, 95%CI 1.006–1.027, respectively). Thromboprophylaxis was protective factor for thrombosis occurrence ($p=0.049$, OR = 0.428, 95%CI 0.184–0.996). In univariate logistic regression analysis, age ($p=0.012$, OR = 1.055, 95%CI 1.012–1.100) and convalescent hyperimmune plasma ($p=0.017$, OR = 3.821, 95%CI 1.275–11.450) were predictive of bleeding, while use and LMWH intermediate/therapeutic dose use was of borderline significance ($p=0.078$, OR = 2.150, 95%CI 0.917–5.041). In multivariate analysis, age ($p=0.007$,

### Table 5 Biochemical characteristics of the patients according to thrombosis and bleeding status

|                        | Thrombosis |                      | Bleeding |                      |
|------------------------|------------|----------------------|----------|----------------------|
|                        | No         | Yes                  | No       | Yes                  |
| ALC (peak), $\times 10^9$/L | 14.20      | 15.00                | 13.18    | 14.20                |
|                        | (3.80–52.00) | (1.90–40.24)        | (3.70–50.60) | (1.50–40.24)        |
| Albumin (nadir), g/dL  | 3.20       | 3.10                 | 3.20     | 3.05                 |
|                        | (2.80–3.80) | (2.70–3.60)         | (2.80–3.80) | (2.82–3.50)         |
| CRP, mg/L               | 21.76      | 25.00                | 22.75    | 23.40                |
| (peak) ($\times$ times the ULN) | (11.40–36.80) | (14.80–41.73) | (11.80–37.20) | (9.91–35.48)        |
| CAR                    | 7.01       | 8.26                 | 7.23     | 7.45                 |
|                        | (3.55–11.83) | (5.15–16.72)        | (3.70–12.39) | (4.20–15.61)        |
| D-dimer, mg/L          | 2.82       | 9.76                 | 2.88     | 6.11                 |
| (peak) ($\times$ times the ULN) | (1.65–6.53) | (3.36–33.20)*        | (1.64–7.44) | (3.12–31.76)*        |

Data are presented as median with 25–75th percentile; *$p<0.05$

ALC absolute lymphocyte count, IQR interquartile range, CRP C-reactive protein, CAR C-reactive protein to albumin ratio, ULN upper limit of normal
OR \(= 1.062, 95\% \text{CI} 1.017–1.109\) and LMWH intermediate/therapeutic dose \(p = 0.044, \text{OR} = 2.438, 95\% \text{CI} 1.023–5.813\) were prognostic factors for bleeding. Continuation versus discontinuation of BTKi was not predictive of thrombosis or bleeding occurrence in the patients with CLL who were receiving BTKi at the time of severe COVID-19 infection \(p < 0.05\).

**Discussion**

CLL is the most prevalent leukemia in the western world, hence the need for improved understanding of COVID-19 in this group of patients is essential, particularly since patients with CLL are at higher risk of adverse outcomes of COVID-19 \[11\]. Against this background, data about the risk for TE events and bleeding complications in CLL patients with COVID-19 is scarce.

In the present cohort, the rate of thromboembolic events in CLL patients with severe COVID-19 was 11.1% (51/460), with PE being the most frequent (8.0%, 37/460). No significant differences were observed in CLL patients with or without thrombosis in terms of baseline patient characteristics, comorbidities and COVID-19-related symptoms. The published data by Chatzikonstantinou et al. \[12\] reported the VTE rate of 6.2% in the study that included 941 CLL patients with COVID-19. The study of 124 patients with various hematological malignancies \[18\], of whom 21 were patients with CLL, reported the rate of VTE of 8%, while the rate of composite thrombotic events (arterial and venous) was 13.4%. Besides the limitation of small patient numbers, direct comparison of this study and ours is of questionable relevance because the higher rate of cumulative thrombotic events in the former could be due to inclusion of particular

**Table 6** Univariate and multivariate logistic regression analyses with thrombosis and bleeding as dependent variable

| Variable                          | Univariate | Multivariate |
|----------------------------------|------------|--------------|
|                                  | OR 95% CI for OR | p          | OR 95% CI for OR | p          |
| Thrombosis                       |            |              |            |              |
| Steroids for COVID-19            | 5.141      | 1.220–21.665 | 0.026      | 2.654       | 1.182–5.958 | 0.018      |
| Anti-IL6 or anti-IL6R            | 3.744      | 1.942–7.215  | <0.001     | 1.022       | 1.007–1.038 | 0.005      |
| Admission to ICU                 | 3.086      | 1.707–5.578  | <0.001     | 1.025       | 1.001–1.051 | 0.042      |
| D-dimer (x times the ULN)        | 1.016      | 1.006–1.027  | 0.002      | 0.199       | 0.061–0.645 | 0.007      |
| CAR                              | 1.030      | 1.007–1.052  | 0.009      |              |            |            |
| Thromboprophylaxis               | 0.428      | 0.184–0.996  | 0.049      |              |            |            |
| Other cardiovascular diseases     | 2.316      | 1.000–5.366  | 0.050      |              |            |            |
| Continued vs. stopped BTKi       | 1.157      | 0.433–3.092  | 0.772      |              |            |            |
| Bleeding                         |            |              |            |              |            |            |
| Age                              | 1.055      | 1.012–1.100  | 0.012      | 1.062       | 1.017–1.109 | 0.007      |
| Convalescent hyperimmune plasma use | 3.821      | 1.275–11.450 | 0.017      |              |            |            |
| LMWH intermediate/therapeutic dose use | 2.150      | 0.917–5.041  | 0.078      | 2.438       | 1.023–5.813 | 0.044      |
| Continued vs. stopped BTKi       | 1.086      | 0.342–3.452  | 0.888      |              |            |            |

IL-6 interleukin 6, ULN upper limit of normal, CAR C-reactive protein to albumin ratio, LMWH low molecular weight heparin, BTKi Bruton tyrosine kinase inhibitors

Figure 2 presents the ROC curve for D-dimer in distinguishing CLL patients with COVID-19, with and without thrombosis (AUC = 0.709, \(p < 0.001\)). At a cut-off D-dimer value of \(4 \times \text{ULN}\), the sensitivity and specificity were 72% and 63%, respectively.
hematological malignancies with well-established higher risk for thrombosis (e.g., plasma cell dyscrasia and myelo-proliferative neoplasms). Comparisons with the general population with COVID-19 are also hindered by various confounding factors, not least of which is the fact that the rate of thrombosis depends largely on disease severity and, consequently, the hospital department (ICU vs. general ward): indeed, the disclosed rates of VTE in critically ill patients in ICU vary between 25 and 69%, in contrast to 7% in general wards [19]. In a systematic review and meta-analysis, the prevalence of VTE in non-ICU and ICU patients were 7.9% and 22.7%, respectively, while the prevalence of PE in non-ICU and ICU patients were 3.5% and 13.7%, respectively [20].

When diagnosed with COVID-19, 175 (34.3%) patients of the present cohort were receiving active CLL-directed therapy. BTK inhibitors were the most frequent CLL-directed therapies, followed by venetoclax. There were no significant differences regarding the type and (dis)continuation of CLL treatment between CLL patients with or without thromboembolic events related to COVID-19, including BTKi. Several possible reasons could account for this finding. First, no CLL-directed specific treatment was associated with an increased risk of thromboembolic events. Second, the treatment was stopped in the majority of CLL patients (80.5%) after the COVID-19 diagnosis was established. Third, the potential beneficial effect of BTK inhibitors on the amelioration of the COVID-19 clinical course [21] was principally due to the modulation of immunological response [22, 23], other than through the notable platelet inhibition effect [24] of BTK inhibitors. Lastly, a small number of CLL patients included in the study were treated with therapeutic options other than BTK inhibitors, which somehow limited the statistical analysis.

Focusing on the potential impact of pharmacological treatment for COVID-19 on the occurrence of thrombosis in the present cohort, patients who were administered corticosteroid therapy and anti-IL6 or anti-IL6R monoclonal antibody were significantly more often diagnosed with thromboembolism. Further, in univariate logistic regression analysis, admission to ICU and use of anti-IL6/anti-IL6R and corticosteroids were predictive of thrombosis occurrence. Anti-IL6 or anti-IL6R monoclonal antibodies have been extensively used in order to ameliorate the hyperinflammatory state. A previous report [25] pointed out a transient surge in D-dimer levels and an increased risk of death secondary to thromboembolism. The limitations of that study were the small number of patients (n = 24), the retrospective nature of the study, and the non-specified severity of COVID-19. Overall, further investigation is warranted regarding the possible relationship between the use of anti-IL6 or anti-IL6R monoclonal antibodies and thrombotic risk thoroughly. In our study, the use of convalescent hyper-immune plasma was more common among patients who experienced bleeding, in contrast to patients who did not experience bleeding. Coagulation profile of human COVID-19 convalescent plasma was found to be impoverished with coagulation factors and, consequently, has prolonged coagulation time [26]. Such a profile might contribute to hemostasis impairment and higher incidence of bleeding events.

D-dimer levels have been extensively studied in COVID-19. It was recognized as a marker of adverse outcome of infection [27] and as an indicator of VTE. Our analysis showed that high CAR and D-dimer values were predictive of thrombosis occurrence also in the context of CLL. Evidently, coagulopathy in COVID-19 infection, coupled with malignancy related coagulopathy, results in state of highly elevated risk of thrombosis development [28, 29]. A higher D-dimer cut-off level in our cohort of COVID-19 CLL patients corresponded to the higher D-dimer levels found in cancer patients with COVID-19 [30], emphasizing the need for strict follow-up of this specific group of patients. Albumin level, as an acute phase reactant, has been associated with both the adverse outcome of COVID-19 and the development of thrombotic events during COVID-19. Hypoalbuminemia as a consequence of acute or chronic inflammation or increased albuminuria can contribute to the development of thrombosis, because of albumins anticoagulant and antiplatelet characteristics [31–33].

Similar to the general population, the admission to ICU was found to be predictive of thrombosis occurrence. This finding was one of the initial hallmark observations of COVID-19 infection, which has been later extensively confirmed [34–36]. The combination of COVID-19 disease severity of patients in ICU, long list of risk factors related to ICU conditions and treatment and solely patients’ characteristics (including malignancies and comorbidities), lead to a detrimental combination for thrombosis development.

Most CLL patients included in the study were administered thromboprophylaxis (90.5%). In keeping with the literature [37], thromboembolic events were significantly more frequent among CLL patients without thromboprophylaxis than those with thromboprophylaxis. The rate of thromboembolism was lower in patients who were administered prophylactic anticoagulation, in comparison with intermediate and therapeutic anticoagulation. However, this latter finding should be cautiously interpreted considering that higher dosages of anticoagulation therapy were probably administered to the patients with more severe clinical course of COVID-19. In addition, it was shown that the use of thromboprophylaxis is associated with lower mortality rate in severely ill COVID-19 patients [38].
Higher doses of anticoagulation were universally recognized as major drivers of bleeding complications [9, 39, 40]. In our study, 5.0% (23/468) had bleeding events, of which more than 50% were classified as major. Patients treated with intermediate/therapeutic doses of LMWH had a higher rate of bleeding than those treated with prophylactic doses of anticoagulation (8.1% and 3.8%, respectively). That said, the risk of bleeding in these patients depends on numerous factors besides the dosage of anticoagulation therapy, including age, CLL disease status (watch and wait or active disease), severity of COVID-19, comorbidities, and inherited or acquired coagulation abnormalities. Of note, we did not identify any association between CLL-specific treatment with BTK inhibitors and the occurrence of a bleeding episode.

The COVID-19 pandemic has raised questions regarding the changes to therapy for the CLL patients being treated, who tested positive for SARS-CoV2. In our study continuation vs. discontinuation of BTKi was not predictive of thrombosis or bleeding occurrence in the patients with CLL who were receiving BTKi at the time of severe COVID-19 infection. Based on this finding and recently published reports suggesting a possible benefit from the BTKis in the setting of severe COVID-19 infection, and the fact that stopping ibrutinib can result in a disease flare-up in patients with CLL, we may recommend that BTKis therapy should be administered until the risks outweigh the therapy benefits [21, 22].

Our study had several limitations particularly stemming from its retrospective nature, including heterogeneity in the treatment approaches for COVID-19. Additionally, we restricted the analysis to patients with severe COVID-19, thus patients with mild or asymptomatic SARS-CoV-2 infection were not studied.

Conclusions
In conclusion, patients with CLL diagnosed with COVID-19 are at a high risk of thrombosis if thromboprophylaxis is not used, but also at increased risk of bleeding under the LMWH intermediate/therapeutic dose administration. More collaborative studies are needed to define the optimal anticoagulation treatment strategy that will provide sufficient benefit, without harm, for severely ill CLL patients hospitalized with COVID-19. Age, serum CRP, albumin level, and D-dimer are simple, easily accessible parameters and may be good candidates for defining subgroups of CLL patients who are at increased risk for thrombosis and bleeding during COVID-19.

Abbreviations
VTE: Venous thromboembolism; PE: Pulmonary embolism; COVID-19: Coronavirus disease 2019; ICU: Intensive care unit; CLL: Chronic lymphocytic leukemia; ERIC: European Research Initiative on CLL; RT-PCR: Real-time polymerase chain reaction; CIRS: Cumulative illness rating scale; ALC: Absolute lymphocyte count; CRP: C-reactive protein; ECMO: Extracorporeal membrane oxygenation; OR: Odds ratios; CI: Confidence interval; ROC: Receiver operating characteristic; SLL: Small lymphocytic lymphoma; MBL: Monoclonal B-cell lymphocytosis; BTKi: Bruton tyrosine kinase inhibitors; PI3K: Phosphatidylinositol-3-kinase inhibitors; IL-6: Interleukin 6; LMWH: Low-molecular-weight heparin; DOACs: Direct oral anticoagulants; CAR: C-reactive protein to albumin ratio; AUC: Area under curve; ULN: Upper limit of normal; SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2.
bureau fees from Roche, Janssen, AbbVie, Celgene, Fresenius, Novonordisk; advisory board participation fees from Janssen, and AbbVie; travel and accommodation expenses from Roche, Janssen, and AbbVie. MoMa received speaker bureau fees from Amgen, honoraria as a consultant from Gilead. JM received honoraria and travel grants from AbbVie, Janssen, Roche, Gilead, and Takeda. JAHR received honoraria and advisory board fees from Janssen, AbbVie, AstraZeneca, Roche, Beigene, Lilly, Gilead, and BMS-Celgene. MD received honoraria from AbbVie, Janssen, Astra-Zeneca, and Novartis. CRM received research funding from Gilead, advisory board participation fees from AbbVie, Gilead, Janssen, Astra-Zeneca, Takeda, and Roche; speakers bureau fees from Janssen, Gilead, and AbbVie. TM received honoraria from AbbVie, Janssen, Astra-Zeneca, Gilead, Roche, and Alexion; advisory board participation fees from AbbVie, Astra-Zeneca, Janssen, Alexion, Morphosys, and Suneesi. RM received honorarium from Janssen, AbbVie, and Astra-Zeneca. MAP received advisory board participation fees from Janssen, AbbVie, Astra Zeneva, and Merck; speaker’s bureau fees from Janssen, AbbVie, Astra-Zeneca, and Janssen; consultant (but no fees) for San‑ doz; travel accommodation from Amgen and Gentilli. GR received consultancy fees and honoraria from AbbVie, Astra-Zeneca, and Janssen. MaMo received consultancy fees from Gilead srl. GMR received consultancy fees from AbbVie, Gilead, and Janssen; research funding from Gilead. MS received consultancy fees, advisory board participation fees, travel grants, honoraria from Janssen, Gilead, Roche, Janssen, Astra-Zeneca, AbbVie. MS received, AstraZeneca, Gilead, Janssen, and Roche. PS received funding from Gilead, advisory board participation fees from AbbVie and Janssen; honorarium AbbVie, Janssen, and Astra-Zeneca. SEA received speaker bureau fees from Janssen, and Takeda. LT received advisory board participation fees from Janssen, Roche, AbbVie, Gilead, Takeda; research funding from Janssen, Roche, Takeda, and Gilead. EVDS received teaching activities fees from AbbVie; speaker fees from Janssen. MV received advisory board participation fees from Janssen, Roche, Astra Zeneva, Beigene; speaker fees from AbbVie. AJ received consultancy fees from Astra-Zeneca, Janssen, Novartis, and Sanofi; advisory board participation fees from Astra Zeneva, Janssen, Sobi, Novartis, Sandoz, MSD, and Incyte, Beigene; speaker fees from Astra-Zeneca, Janssen, Sobi, Incyte, Novartis, AbbVie, Amgen, Takeda, and Beigene. AE received honoraria and advisory boards fees from Janssen, AbbVie, Novartis, Beigene, and BMS-Celgene. AV received speaker’s bureau fees from italfarmaco and Gilead; advisory board participation fees from Janssen and Takeda. CV received honoraria from Janssen. IM received speaker fees from Janssen, Roche, AbbVie, Sandoz. FM received fees from Janssen, and Gilead. TW received research funding from Roche; honoraria for advisory board, and research funding from Janssen; honoraria, advisory board participation fees, and travel grant from AbbVie; speaker’s bureau fees from Gilead. TC, AK, GK, AAG, DA, MB, MRG, AC, SC, JCC, GC, GG, LDP, MRDP, GDP, CD, MD, DD, ME, MMK, LF, AF, MF, MO, MG, YH, TH, DI, GBI, OBK, EK, JLG, DL, EL, LM, RM, MaMa, MaMot, RN, JO, LO, MP, IP, VMPI, GQ, LR, JGC, SS, GS, AS, OS, NS, TT, DTR, ST, MGV, EWS, MY, AR have no conflict of interest to disclose.

Author details
1 Lymphoma Center, Clinic for Hematology, University Clinical Center of Serbia, Belgrade, Serbia. 2Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
3Department of Medical Statistics and Informatics, Faculty of Medicine, University of Belgrade, Belgrade, Serbia. 4Hematology Department and HCT Unit, General University Hospital, Belgrade, Serbia. 5University of Belgrade, Belgrade, Serbia. 6Hematology Department, University Clinical Center of Belgrade, Belgrade, Serbia. 7Hematology Department, University Clinical Center of Serbia, Belgrade, Serbia. 8Hematology Department, University of Belgrade, Belgrade, Serbia. 9Institute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece. 10University-Vita-Salute San Raffaele and IRCCS, Ospedale San Raffaele, Milan, Italy. 11Centre for Atherothrombosis and Metabolic Disease, Hull York Medical School, Hull, UK. 12Haematology Department, Hospital Universitario de La Princesa, Madrid, Spain. 13Department of Hematology and Central Hematology Laboratory, Innsbruck, University Hospital, University of Innsbruck, Innsbruck, Austria. 14Hematology Department, University of Novi Sad, Novi Sad, Serbia. 15Hematology Department, Hospital Universitario 12 de Octubre, Madrid, Spain. 16Hematology Department, University of Salamanca, Salamanca, Spain. 17Hematology Department, University of Valencia, Valencia, Spain. 18Department of Hematology, Hospital Universitario de Valencia, Valencia, Spain. 19Hematology Department, University of Barcelona, Barcelona, Spain. 20Hematology Department, University of Navarra, Pamplona, Spain. 21Hematology Department, University of Salamanca, Salamanca, Spain. 22Department of Biomedicine and Prevention Hematology, University Tor Vergata, Rome, Italy. 23Department of Biomedicine and Prevention Hematology, University Tor Vergata, Rome, Italy. 24Department of Hematology, University of Padua, Padua, Italy. 25Hematology Department, University of Padua, Padua, Italy. 26Department of Medical Oncology, University of Padua, Padua, Italy. 27Department of Hematology, University of Padua, Padua, Italy. 28Hematology Department, University of Padua, Padua, Italy. 29Hematology Department, University of Padua, Padua, Italy. 30Hematology Department, University of Padua, Padua, Italy. 31Hematology Department, University of Padua, Padua, Italy. 32Hematology Department, University of Padua, Padua, Italy. 33Hematology Department, University of Padua, Padua, Italy. 34Hematology Department, University of Padua, Padua, Italy. 35Hematology Department, University of Padua, Padua, Italy. 36Hematology Department, University of Padua, Padua, Italy. 37Hematology Department, University of Padua, Padua, Italy. 38Hematology Department, University of Padua, Padua, Italy. 39Hematology Department, University of Padua, Padua, Italy. 40Hematology Department, University of Padua, Padua, Italy. 41Hematology Department, University of Padua, Padua, Italy. 42Hematology Department, University of Padua, Padua, Italy. 43Hematology Department, University of Padua, Padua, Italy. 44Hematology Department, University of Padua, Padua, Italy. 45Hematology Department, University of Padua, Padua, Italy. 46Hematology Department, University of Padua, Padua, Italy. 47Hematology Department, University of Padua, Padua, Italy. 48Hematology Department, University of Padua, Padua, Italy.
References

1. Di Minno A, Ambrosino P, Calcaterra I, Di Minno MN. COVID-19 and venous thromboembolism: a meta-analysis of literature studies. Semin Thromb Hemost. 2020;46(7):763–71.

2. Klok FA, Kruip MJA, van der Meer NJM, Arbous MS, Gomers DAMPI, Kant KM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020;191:145–7.

3. Middeldorp S, Coppens M, van Haaps TF, Foppen M, Vlaar AP, Müller MCA, et al. Incidence of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost. 2020;18(8):1995–2002.

4. Haddad T, Kafri Z, Al-Katib A. Coagulation and anticoagulation in COVID-19. Blood. 2021;147(7):70671.

5. Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis Off Publ Infect Dis Soc Am. 2020;71(15):762–8.

6. Iba T, Connors JM, Levy JH. The coagulopathy, endotheliopathy, and vasculitis of COVID-19. Inflamm Res. 2020;69(12):1181–9.

7. Iba T, Levy JH, Levi M, Thachil J. Coagulopathy in COVID-19. J Thromb Haemost. 2020;18(9):2103–9.

8. Al-Samkani H, Karp Leaf RS, Dzik WH, Carlson JC, Fogerty AE, Waheed A, et al. COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection. Blood. 2020;136(4):489–500.

9. Musoke N, Lo KB, Albanese J, Peterson E, Bhargav R, Gul F, et al. Anticoagulation and bleeding risk in patients with COVID-19. Thromb Res. 2020;196:227–30.

10. Rai KR, Jain P. Chronic lymphocytic leukemia (CLL)-then and now. Am J Hematol. 2016;91(3):330–40.

11. Mano AR, Roeker LE, Lamanina N, Allan JN, Leslie L, Pagel JM, et al. Outcomes of COVID-19 in patients with CLL: a multicenter international experience. Blood. 2020;136(10):1134-43.

12. Chatzikonstantinou T, Kapetanakis A, Scarfo L, Karakatsoulis G, Allsup D, Cabrero AA, et al. COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study. Leukemia. 2021;35:3444–54.

13. Hallek M. Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment. Am J Hematol. 2019;94(11):1266–87.

14. Roschewski M, Lionakis MS, Sharmar JP, Roswarski J, Goy A, Monticelli MA, et al. Inhibition of Bruton tyrosine kinase in patients with severe COVID-19. Sci Immunol. 2020. https://doi.org/10.1126/sciimmunol.abd0110.

15. Shatzel JJ, Olson SR, Tao DL, McCarty OT, Danilov AV, DeLoughery TG, Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies. J Thromb Haemost. 2017;15(5):835–47.

16. Chan KH, Patel B, Podel B, Szablea ME, Shaaban HS, Guron G, et al. Tocilizumab and thromboembolism in COVID-19: a retrospective hospital-based cohort analysis. Cureus. 2021;13(5):e15208.

17. Klopman AM, van Helmond NJ, Jukewitje JH, Pruthi RK, Sexton MA, Soto JC, et al. Coagulation profile of human COVID-19 convalescent plasma. Sci Rep. 2022;12(1):637.

18. Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood. 2020;135(23):2033–40.

19. Levy M. Pathophysiology of coagulopathy in hemorrhagic malignancies and in COVID-19. HemaSphere. 2021;5(6):e571.

20. Thachil J, Khorana A, Carrier M. Similalities and perspectives on the two Cs—cancer and COVID-19. J Thromb Haemost. 2021;19(S):1161–7.

21. ElGohary GM, Hashmi S, Styczynski J, Khafar-Dabaja MA, Alblooshi RM, de la Camara R, et al. The risk and prognosis of COVID-19 infection in cancer patients: a systematic review and meta-analysis. Hematol Oncol Stem Cell Ther. 2020. https://doi.org/10.1016/j.hemonc.2020.07.005.

22. Violi F, Cangemi G, Romiti GF, Ceccarelli G, Oliva A, Alessandri F, et al. Is albumin predictor of mortality in COVID-19? Antioxid Redox Signal. 2021;33:139–42.

23. Violi F, Ceccarelli G, Cangemi R, Pipitone F, D’Ardes D, Oliva A, et al. Arterial and venous thrombosis in coronavirus 2019 disease (COVID-19): relationship with mortality. Intern Emerg Med. 2021;16(5):1231–7.

24. Violi F, Ceccarelli G, Loffredo L, Alessandri F, Pipitone F, D’Ardes D, et al. Albumin supplementation dampens hypercoagulability in COVID-19: a preliminary report. Thromb Haemost. 2021;121:102–5.

25. Tan BK, Mainbourg S, Friggen A, Bertolioti L, Douplat M, Dargaud Y, et al. Arterial and venous thromboembolism in COVID-19: a study-level meta-analysis. Thorax. 2021;76(10):970–9.

26. Mansory EM, Siruguppanal S, Lazo-Langner A. Venous thromboembolism in hospitalized critical and noncritical COVID-19 patients: a systematic review and meta-analysis. TH Open Companion J Thromb Haemost. 2021;5(3):e286–94.

27. Jenner WJ, Kanji R, Mirsadaee S, Gue YX, Price S, Prasad S, et al. Thrombotic complications in 2928 patients with COVID-19 treated in intensive care: a systematic review J Thromb Thrombolysis. 2021;51(3):595–607.

28. Patelli R, Chisakul T, Euerl B, Zwicker J. Pharmacologic thromboprophylaxis and thrombosis in hospitalized patients with COVID-19: a pooled analysis. Thromb Haemost. 2021;121(1):76–85.

29. Di Castelnuovo A, Costanzo S, Antinori A, Bersell L, Blandi L, Bonaccio M, et al. Heparin in COVID-19 patients is associated with reduced in-hospital extended thromboprophylaxis. TH Open Companion J Thromb Haemost. 2020(4(1)):e59-65.
mortality: the multicenter Italian CORIST study. Thromb Haemost. 2021;121(8):1054–65.

39. Jiménez D, García-Sánchez A, Rali P, Muriel A, Bikdeli B, Ruiz-Artacho P, et al. Incidence of VTE and bleeding among hospitalized patients with coronavirus disease 2019: a systematic review and meta-analysis. Chest. 2021;159(3):1182–96.

40. Nadkarni GN, Lala A, Bagiella E, Chang HL, Moreno PR, Pujadas E, et al. Anticoagulation, bleeding, mortality, and pathology in hospitalized patients with COVID-19. J Am Coll Cardiol. 2020;76(16):1815–26.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.